Literature DB >> 9669432

Effect of acetate, bicarbonate dialysis, and acetate-free biofiltration on nitric oxide synthesis: implications for dialysis hypotension.

M Noris1, M Todeschini, F Casiraghi, D Roccatello, G Martina, L Minetti, B Imberti, F Gaspari, M Atti, G Remuzzi.   

Abstract

The effect of acetate dialysis (AD), bicarbonate dialysis (BD), and acetate-free biofiltration (AFB) on nitric oxide (NO) synthesis and the implications for dialysis hypotension was studied. The finding that uremic plasma is a potent inducer of NO synthesis by endothelial cells in vitro suggested that the cardiovascular instability of dialysis patients might result from excessive NO formation. Cardiovascular instability is more frequent in patients undergoing AD than BD. To see whether these differences were attributable to NO, we studied the NO synthetic pathway ex vivo in patients undergoing different dialysis procedures. Five patients were treated, in a random order, with AD, BD, and AFB, a technique using a buffer-free dialysate and postdilution of a sterile bicarbonate solution. Each type of dialysis was used for 1 week, comprising three dialysis sessions. A polyacrylonitrile dialyzer was used for all three methods. Before and after the third dialysis, plasma was collected, added to [3H]L-arginine, and incubated with human umbilical vein endothelial cells (HUVECs) for 24 hours. NO synthesis was evaluated as [3H]L-citrulline formation. Plasma concentrations of interleukin-1beta (IL-1beta), a potent inducer of inducible NO synthase (iNOS) in endothelial cells, were also measured. Plasma collected from patients after AD stimulated endothelial NO synthesis more than plasma from the same patients before the dialysis session (pre-AD, 0.173+/-0.028 nmol/10(5) cells v post-AD, 0.280+/-0.093 nmol/10(5) cells; P < 0.05). A slight, although not significant, increase was also observed when HUVECs were incubated with plasma drawn after BD (pre-BD, 0.151+/-0.014 nmol/10(5) cells; post-BD, 0.230+/-0.055 nmol/10(5) cells). AFB did not aggravate the stimulatory effect of uremic plasma on endothelial NO synthesis (pre-AFB, 0.184+/-0.038 nmol/10(5) cells; post-AFB, 0.189+/-0.040 nmol/10(5) cells). Plasma IL-1beta was greater (P < 0.01) after AD than after BD and AFB (post-AD, 0.234+/-0.028 pg/mL; post-BD, 0.124+/-0.019 pg/mL; post-AFB, 0.120+/-0.013 pg/mL). With AD, there was a greater intradialytic decrease in systolic blood pressure than with BD or AFB. Weight and blood volume loss and sodium balance were similar in AD, BD, and AFB. These data were consistent with the possibility that NO and cytokines, released in excessive amounts during AD, may contribute to hemodynamic instability.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9669432     DOI: 10.1053/ajkd.1998.v32.pm9669432

Source DB:  PubMed          Journal:  Am J Kidney Dis        ISSN: 0272-6386            Impact factor:   8.860


  11 in total

Review 1.  A brief review of intradialytic hypotension with a focus on survival.

Authors:  Jason A Chou; Kamyar Kalantar-Zadeh; Anna T Mathew
Journal:  Semin Dial       Date:  2017-06-29       Impact factor: 3.455

2.  Acetate, a Short-Chain Fatty Acid, Acutely Lowers Heart Rate and Cardiac Contractility Along with Blood Pressure.

Authors:  Brian G Poll; Jiaojiao Xu; Seungho Jun; Jason Sanchez; Nathan A Zaidman; Xiaojun He; Laeben Lester; Dan E Berkowitz; Nazareno Paolocci; Wei Dong Gao; Jennifer L Pluznick
Journal:  J Pharmacol Exp Ther       Date:  2021-01-07       Impact factor: 4.030

3.  Comparison of sustained hemodiafiltration with acetate-free dialysate and continuous venovenous hemodiafiltration for the treatment of critically ill patients with acute kidney injury.

Authors:  Masanori Abe; Noriaki Maruyama; Shiro Matsumoto; Kazuyoshi Okada; Takayuki Fujita; Koichi Matsumoto; Masayoshi Soma
Journal:  Int J Nephrol       Date:  2011-05-14

4.  Section 5: Dialysis Interventions for Treatment of AKI.

Authors: 
Journal:  Kidney Int Suppl (2011)       Date:  2012-03

5.  Conversion from acetate dialysate to citrate dialysate in a central delivery system for maintenance hemodialysis patients.

Authors:  Eun Ji Park; Su Woong Jung; Da Rae Kim; Jin Sug Kim; Tae Won Lee; Chun Gyoo Ihm; Kyung Hwan Jeong
Journal:  Kidney Res Clin Pract       Date:  2019-03-31

6.  Citrate anion improves chronic dialysis efficacy, reduces systemic inflammation and prevents Chemerin-mediated microvascular injury.

Authors:  Sergio Dellepiane; Davide Medica; Cesare Guarena; Tiziana Musso; Alessandro Domenico Quercia; Gianluca Leonardi; Marita Marengo; Massimiliano Migliori; Vincenzo Panichi; Luigi Biancone; Francesco Pizzarelli; Giovanni Camussi; Vincenzo Cantaluppi
Journal:  Sci Rep       Date:  2019-07-23       Impact factor: 4.379

7.  Mechanism of arrhythmias during the infusion of Ringer's acetate and Ringer's lactate solutions during cardiac surgery: new insights.

Authors:  Sébastien Redant; Yael Langman; David De Bels; Rachid Attou; Patrick M Honore
Journal:  Crit Care       Date:  2019-12-18       Impact factor: 9.097

8.  Effects of acetate-free citrate dialysate on glycoxidation and lipid peroxidation products in hemodialysis patients.

Authors:  Atsumi Masuda; Shinji Hagiwara; Mitsuo Tanimoto; Fumiko Kodama; Kozue Okumura; Nao Nohara; Mayumi Matsumoto; Masayuki Maiguma; Keisuke Omote; Hiroaki Io; Atsushi Kurusu; Isao Ohsawa; Yoshio Shimizu; Chieko Hamada; Satoshi Horikoshi; Yasuhiko Tomino
Journal:  Nephron Extra       Date:  2012-09-27

9.  Post-dilution on line haemodiafiltration with citrate dialysate: first clinical experience in chronic dialysis patients.

Authors:  Vincenzo Panichi; Enrico Fiaccadori; Alberto Rosati; Roberto Fanelli; Giada Bernabini; Alessia Scatena; Francesco Pizzarelli
Journal:  ScientificWorldJournal       Date:  2013-12-03

10.  Replacement of acetate with citrate in dialysis fluid: a randomized clinical trial of short term safety and fluid biocompatibility.

Authors:  Gunilla Grundström; Anders Christensson; Maria Alquist; Lars-Göran Nilsson; Mårten Segelmark
Journal:  BMC Nephrol       Date:  2013-10-09       Impact factor: 2.388

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.